Healthcare Industry in 2017: Hype and Speculation Loom Over Technology Trends and Potential Policy Shifts
March 2, 2017 | Frost & SullivanEstimated reading time: 2 minutes
Despite global political uncertainties and a sluggish economic outlook for 2017, the global healthcare industry is set for an invigorating year due to a partial realisation of major healthcare policies and initiatives, technology advancements and value-based care driving the adoption and need for consumer-centric targeted therapies. Future drugs and medical devices will be more targeted to meet the unique needs of emerging markets (e.g. China, India, Brazil) which demonstrate high growth opportunities compared developed markets (e.g., US, and Western Europe. Growing at a CAGR of 4.8%, the industry is likely to reach revenue of $1,731.8 billion. Current predictions and trends encouraging transformation include:
- Growth in RPM (remote patient monitoring) will start to accelerate beyond previous projections based on a convergence of regulatory, technology and ergonomic factors.
- A selective churn in the health app space will differentiate small number of vetted apps that will emerge as the best choice for serious health users.
- Life sciences and device industries will experience an increase in collaboration as well as merger and acquisition activities as they design products to prevent the onset of chronic and degenerative diseases.
- Artificial intelligence (AI) will play an important role in helping radiologists better interpret scans, reduce scan times, improve workflow efficiency and improve quality. AI will also make medical implants smarter as a way to intelligently regulate specific health conditions.
- Alternate payment models will drive the demand for next-gen revenue cycle management solutions. The adoption of alternative payment models will drive the usage of robust and agile analytics software that automates reporting and visualisation of patient-specific information.
- Immunotherapy will become part of the toolbox for treatment of various types of cancers. Immuno-oncology will remain hot as leading pharmaceutical companies race to market the first chimeric antigen receptor T-cell (CAR-T) therapy in 2017.
- Decreasing cost of next-generation sequencing tests to below the $1,000 mark will shift the application focus from research to clinical use cases.
The new analysis, Healthcare Industry Outlook, 2017, which is part of Frost & Sullivan’s Advanced Medical Technologies Growth Partnership Service program, explores how the global healthcare landscape is expected to evolve in 2017. It identifies key trends impacting the industry from lifesciences, medical technologies, remote patient monitoring, healthcare information technologies, care delivery and business model perspectives.
“2017 will be a tipping point for mainstream adoption of popular digital health solutions (e.g. Wearables, Telehealth), and transition of noble technologies from research to actionable clinical applications (e.g. POCT Dx tools, AI, Robotics, and Image-guided therapies),” notes Frost & Sullivan Transformational Health Research Analyst Kamaljit Behera.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Suggested Items
Big Win for Defense Production Act Budget Allocation in FY24 Budget
04/23/2024 | I-Connect007 Editorial TeamOne year ago, President Biden issued a determination that chips and packaging are critical for national security. Since that time, much work has been done to continue the conversation in Washington, elevating the importance of the entire chips value chain, and including printed circuit boards and substrates, without which chips cannot operate.
Zentech’s Board of Directors Announces the Return of Matt Turpin as President and CEO
04/22/2024 | Zentech ManufacturingTurpin draws upon over 35 years of experience in the electronics industry and has an 18-year history with Zentech. He previously served as President and CEO from 2006 to 2019 after which time he has remained active in the EMS industry as an advisor to Zentech and other industry organizations.
Aaron Woolf, Dylan Peterson Join SIA Team
04/22/2024 | SIAThe Semiconductor Industry Association (SIA) announced Aaron Woolf and Dylan Peterson have joined the SIA team. Woolf will serve as director of global policy for economic security and Peterson will be a communications associate. SIA represents 99% of the U.S. semiconductor industry by revenue and nearly two-thirds of non-U.S. chip firms.
It’s Only Common Sense: OCCAM—the Time Is Now
04/22/2024 | Dan Beaulieu -- Column: It's Only Common SenseOne of my favorite books is a little tome called Who Moved My Cheese? Even those of you who don’t spend a lot of time reading books have at least heard of it and know that it refers to people, especially in business, who are so stuck in their ways that they get upset when something changes. In our business, we know this kind of thinking is especially true. In fact, it always makes me laugh when one of my innovative friends finds a new way to do something and is afraid that someone will steal his idea. I always tell him that no one in our business, especially a PCB engineer, has ever thought about someone else’s innovative idea enough to steal it.
Digitalisation and ESG
04/19/2024 | Marina Hornasek-Metzl, AT&SDigitalisation and ESG are prominent and high-priority topics in the global business community. The first focuses on applying technology throughout the value chain to produce faster, smarter, and more desirable business outcomes. The latter emphasises the broader value a business is expected to create for its stakeholders from an environmental, social, and governance perspective.